StoneX Group’s Phio Pharmaceuticals PHIO Stock Holding History

StoneX Group’s Portfolio PHIO Stock Details PHIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-11,828	Closed	-$12.4K	–	1174
2025 Q4	$12.4K	Buy	+11,828	New	+$18.9K	﹤0.01%	992

Other funds holding PHIO

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Cetera Investment Advisers Schaumburg, Illinois $94B AUM 20.14% 1-Year Est. Return

VFT

Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

SRL

Scientech Research LLC Jersey City, New Jersey $120M AUM 73.62% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return

StoneX Group's PHIO Position: Q1 2026 in Review

StoneX Group sold out of Phio Pharmaceuticals (PHIO) in Q1 2026, closing a stake of 11,828 shares — an estimated $12.4K sold.

StoneX Group first reported a position in PHIO in Q4 2025 and held it in 1 quarter. The position peaked at $12.4K in Q4 2025. 24 funds tracked by Wall St. Rank hold PHIO as of Q1 2026.

StoneX Group reported no remaining Phio Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
StoneX Group sold 11,828 Phio Pharmaceuticals shares in Q1 2026, an estimated $12.4K.
StoneX Group first reported a position in Phio Pharmaceuticals in Q4 2025 and held it in 1 quarter.
StoneX Group's Phio Pharmaceuticals position peaked at $12.4K in Q4 2025.
24 funds tracked by Wall St. Rank held Phio Pharmaceuticals as of Q1 2026.

Based on StoneX Group's 13F filing for Q1 2026, filed 14 May 2026.